Speaker 1 [00:00:05] All right. Well, thanks, everybody, for joining. And if you’re plugged into the robotics world at all, you know what a treat it is to have each of the individuals that are sitting on the stage today, the body of work and the experience, a substantial start up, big corporate advisement from the ASC side, all the things we’re going to talk about today. And that sets up the stratification robotics and especially we’re going to probably focus on the soft tissue side of things, giving our audience here today. And then obviously the influence that the ASC world has had and is going to have and the different formats coming out today. So if you can introduce yourselves and maybe share the perspective from which you’ll be thinking about the questions.
Speaker 2 [00:00:46] All right. My name is Evelyn T. I’m a partner at LSC Life Sciences Consultants. It’s a boutique consulting company that works across the tech and biopharma space. And we work with some of the biggest names in industry. We work mainly strategics and investors across to do growth strategies such as market assessments, due diligence. And we have deep domain expertise across a number of areas, including orthopedics, SC channels and robotics. I co-lead the MedTech Investor Practice and I further specialize in orthopedics, structural heart and vascular. I look forward to being on this panel very one today.
Speaker 3 [00:01:22] Hi, Scott Henican, a former CEO of Verb Surgical, where we did a soft tissue robot, formerly NuVasive Seaboard, where we’re doing spine robots. And this is for dental robots, interventional cardiology robots. So in digital platforms. So I’m coming at it from all that now on boards of a number of cardiology surgery companies.
Speaker 4 [00:01:46] Hi everyone. My name is Mike Clothier. I lead business development for the surgical operating unit for Medtronic, which includes our open, laparoscopic and robotic tools and offerings. I’ve been with the company almost six years, so from the infancy of our robotic program and that’s the perspective I’ll be bringing, is kind of that big player in the market and how robotics is going to continue to evolve.
Speaker 5 [00:02:12] And my name is Greg Roach, CEO of Distal Motion. I’ve been there about 125 days. My prior two years I spent at Avatar Medical. So both soft tissue multiport robotic companies and then the previous four years before that, I was responsible for launching Rossa, which is Zimmer Biomet total new robot. So I’ve been in robotics six the last 6 or 7 years all over the world.
Speaker 1 [00:02:38] Great. All right. So we’re going to jump right into this and I’m going to focus on I want to kick the clock just so I know where we are in this, the stratification of robotics and soft tissue surgery. And my start, Greg, with you, you’ve you’ve obviously been involved with Viterra. You come from New York, a C side as well, and now leading distal motion. So what have you seen and what are you focusing on from your perspective with distal in the leader there on this stratification?
Speaker 5 [00:03:07] Yeah. So I think one of the things you look at, there’s really two categories. You have clinical barriers and you have economic barriers, especially when you talk about outpatient surgical hospitals or ACS. So the learnings for me are everything matters from a clinical perspective. To get adoption, you have to have ease of use. You have to have simple integration, you have to work around the workflow of that particular site of care versus trying to force the work workflow of the tool that you’re using. So that’s really, really important. The other burdens from an economic perspective, obviously lower reimbursement when you move to those sites of care. So you have to be conscious of that. But inventory space, all of those things really matter. So it’s one of the reasons I ran the distal motion. Small form factor, perfect for outpatient and perfect for minor procedure rooms, the ability to do both high and low acuity cases. And I think we’re all seen you know, when you think about the patients we have to move to these sites of care is just less burden on the patient, better place for them to have surgery, especially the lower acuity surgery. So there’s a lot to do, I guess, you know, multifactorial to really understand whether or not you have a product that will fit. And again, I’ll just take the learning from from Zimmer. I mean, I think about 30 plus percent of our robots in the first three years were in the outpatient environments. And again, all of those things we had to figure out. And you don’t really think about how inventory stored and logistics around sterilization, but all those details matter. So there’s you have to have the perfect product to really cross those boundaries.
Speaker 1 [00:04:50] Scott Early days, a verb. Did we even think about the stratification robotics at that point in time in soft tissue surgery?
Speaker 3 [00:05:00] Yeah, I believe so. I mean, look, I, I every market, you know, is going to start with some generalized tool, like, you know, the Model T, but we know we’re going to end up with off road vehicles and sports cars and all the like. So I think we’re at an exciting time where, hey, there’s this intuitive system that is an incredible invention, and I’m sure the newest version is going to be incredible as well. But does that fit all of these different, you know, segments of soft tissue where, hey, can I offload some capacity to do this particular hernia procedure or this particular and make it, as he talked about, you know, more available economically to each of these different markets around the world as well as each of these different segments clinically that also exist. So we were thinking about that and how we may end up having to have three robots to have a portfolio to meet all the different needs either clinically, economically or geographically.
Speaker 1 [00:06:06] And Mike, so how’s how is Medtronic thinking about that? You know, you put your first order in the water with you go. And that architecture probably was added even before the ASC was thought about candidly being their early days. So. So how? Were you thinking that portfolio moving forward? Is that a ASC model? Is it a hospital model? Are you going to try and split them?
Speaker 4 [00:06:27] Yeah. I think the the idea first was to focus on the hospital market, where historically Medtronic’s surgical instruments were being utilized and the surgeons were performing surgery there. So we focused the robot on applications in that area. But the modular design, I think where you’re you’re kind of going, Joe, is very much meant to be something that could be adopted and adapted to the ASC kinds of markets where maybe you don’t need all four arms, you might have a three arms or being able to leverage that same product into the ASC, maybe lower acuity types of cases. Maybe they don’t need the advanced vessel sealing or stapling products, but still a product that could be adapted towards those additional markets.
Speaker 1 [00:07:15] And Evelyn, going into the ASCs, you’ve got a specialization in that area around that. And how does surgeons view the use of robotics? The same surgeon think about it when she’s in a hospital or an outpatient or an AC.
Speaker 2 [00:07:29] Yeah, that’s a really interesting question. So when you think about the entire population of surgeons, they’re definitely not a homogeneous population. The definitely different segments within that. And where we and when you think about scaling up, it’s not the same as starting up. And where we are in the technology adoption curve is that I think we’re one of the early adopters and innovators, and these surgeons on here are much more comfortable and open to using robotics than those who have yet to adopt robotics. And so if we want to think about winning over the early and late majority, we need to think about servicing these potential customer sets who will be using and view robotics in a very different way from the current customer base. I think some of the perceptions that we have heard from surgeons about using robotics is that robotics can lead to a longer procedure time, longer to set up time, which affects the procedure efficiency. It can lead to higher costs, which of course affects the business economic success of their practice. And some of them believe that it can lead to an erosion of their surgical skills, which we all know surgeons really pride themselves on. I’m sure many of you here, myself included, and my fellow panelists, of course, a great believer in the power of robotics. But we have to recognize that this sentiment is not necessarily shared by all surgeons and their staff. You know, like I’m sure you know, all of us here can think of at least 1 or 2 surgeons who think of themselves as like Dr. Strange. You know, they have a really high ability, great guidance, ability of their hands. And so when we want to scale up in a market, we have to think about addressing some of these perceptions. But really, regardless of where surgeons stand in robotics right now, generally speaking, all surgeons do view robotics as the way of the future because they believe that technological improvements will ultimately allow robotics to always deliver better patient outcomes.
Speaker 1 [00:09:25] Intuitive has done a very sort of clever and had the time to do this. And I just want to toss this out because it comes into play. They’ve built both a technological moat and and financial moat, especially with the major trend in leasing. So the cohort we’re selling to right now in ASCs is different than an institutionalized buyer. And Michael, start with you, I guess, on this one. How how should we be thinking about as a community putting soft tissue robots into an ASC? Consider the future of financing that and placing those robots.
Speaker 4 [00:09:59] Yeah, I think it’s a it’s a really interesting question. I think you’re you’re right that especially for early stage robotics companies that Medtronic you know, we’re not going to have the the margins out of the gate that an intuitive has so they have a lot of pricing capability to be able to to to leverage there. But I think you have to be creative. I mean, there are different ways to do that. And for example, in the Medtronic case, we do have instruments across the board, open, laparoscopic and robotic that we might be able to bundle in a certain way and be able to offer to customers that maybe Medtronic can’t. And in offering similar performance across those platforms with those instruments. So we just have to figure out a different way to compete maybe in and try and match some of those business models. That intuitive is pioneering. But we’ve got to find the right niche and the right product offering for those markets.
Speaker 1 [00:10:52] Scott, on the same point that Mike just made, we have to figure out a way to compete. How many different ways are there to compete? Finance outcomes, patient selection.
Speaker 3 [00:11:03] I go back to what we started using the term digital surgery at verb surgical across all these things. And and I just view robotics as one part of improving surgery. It’s like, how do we democratize surgery around the world to improve outcomes, you know, equalize performance at a low cost. And robotics are part of that solution to scale into that. And again, I go back to my comments about sports cars and, you know, on off road vehicles, like I think you can compete on having a portfolio of robots to say, Hey, I’ve got this like $30,000 ventral hernia robot or I’ve got this, you know, $30,000 for this robot and you only need these two instruments to do this procedure that’s easier to adopt for hospitals around the world. And you go to the presentation that you would have made this morning and you project 25 years forward where surgery is going to be done volume wise, where’s the population growth? And we need to make these solutions more economical and more adaptable. Also, with a connected platform, we’re going to have remote surgery that’s going to happen in the next 20 years. So there’s all of these different between data, between training, between product, between bundling, which, you know, J and J. You know, about, you know, Verb and Medtronic, we have the biggest portfolios by far of procedural surgery days. So back to my volcano days. Anyone coming in, they may have a little better Ivus product than Volcano did, but we had 20 different products and use eight of them. And here’s your free volcano system adverb. The plan was, hey, use $6 million of instruments, here’s your free eight robots. You know, the margin was still 70% plus. I’m sure their model can be the same week. So that’s a whole different way to compete with intuitive. And so the numbers that were shown, I mean, market penetration still up 15% in the US, like outside the U.S., much lower in Europe, much lower other places. We’re in the early beginning of democratizing surgery performance wise around the world. And it’s going to take all of those and more different ways to make it a reality. My view.
Speaker 1 [00:13:12] Greg, as you position this the motion to be one of the earlier soft tissue robotic systems that will be selling into ASC as well as hospitals, but staying on that ASC model and the stratification, what are you thinking about as a leader there? What do you think about as a platform company and then what’s going to make you attractive from one of the big strategics that might be able to come in and pick up a distal motion?
Speaker 5 [00:13:34] Well, first I’ll say we’re building the business for us.
Speaker 1 [00:13:38] Selling you ready to win?
Speaker 5 [00:13:39] I do appreciate that. But, you know, for for us, we’re very intentional. And this is before me. Our founder, Michael Frederick, was very intentional about saying no. And one of the lessons I learned actually in my last role was you cannot be the master of everything. So to enter the market and expect that you can master robotics, instrumentation, now visualization and advanced visualization data and AI TelePresence tell us surgery, I mean, it’s an impossibility for distill motion. So what we what we chose to do was build an open platform. So we’re going to master. And, you know, I always say it’s very difficult to make something so complex, very simple, but we try to simplify our platform for ease of adoption for, you know, to adopt this the platform into a site of care. But really the gist of it is to be open. So we are we’re allowing surgeons to choose their visualization technology. We don’t think we’re going to be better than Stryker or Staats or Olympus in that category. Obviously. ICG multispectral imaging, there’s so many tales there. We don’t expect we’re going to build a better stapler than JNJ or Medtronic, you know, energy devices. So we’re you know, we we think that that part of the solution is choice, allowing, you know, building a platform that you can use, you can justify. So it’s not an anvil to a nail. It’s it makes sense to use it in these lower acuity cases and giving the surgeons the ability to choose what they feel is best for their patients at that particular site of care.
Speaker 1 [00:15:17] I will. I’m curious about your opinion on this one. I wonder what you’re thinking. So. You spent a lot of time in the asks and you’ve solicited the owners, the PR firms and the work teams that decide which, which, which vehicle they want to drive. Who influences those decisions? Obviously not in every ASC, but in general the manufacturers are not really paying attention to.
Speaker 2 [00:15:43] Yeah. So. So right now, about two thirds of ASCs do not have an orthopedic robot. So really, the that that means there there’s an opportunity for a strategic to take that market leadership position. And surgeons right now, they’re operating across two, three settings, right? One in an inpatient setting and then another time in an outpatient, whether or not it’s HPD or an ASC setting. So this same surgeon with access and good exposure to a particular robot or robotic brand in an inpatient setting will have a higher propensity and a really good impression of the same robot or robotic brand in an outpatient setting. The question is if he can, he or she can make the economics work and if the strategic can come up with an innovative business model that reduces or shares that high capital costs. And so to your question about who makes the decisions right now, and in AC, it’s not only the older surgeons, the ones who bring in all the business and to a certain extent some PE companies, because PE companies are now coming into the arena and they’re buying up a lot. The ACS like MCI, which is one of them that just got bought up by a company. But that being say that being said about the older surgeons, having the influence is really promising to note that it’s the younger surgeons that generally speaking, that have the most are the most enthusiastic and optimistic about surgically surgeries being supported by robotics, whether or not it’s orthopedics or general surgery. And although this younger, not younger cohort right now is still the minority compared to the entire population of surgeons. And as of right now, still do not have the influence and buying power within the AC. That’s all going to change very quickly the next 5 to 10 years. And if you if you consider all the incoming cohorts or surgeons who are going to be graduating, you’re going to see this group of robotic enthusiast forming a much larger part of the market space. And these younger cohorts of surgeons think very differently about robots then the older cohorts. And so companies really need to think about how these younger surgeons think about their mindsets and how they go about buying decisions are robots and think about also investing brand loyalty right now. I mean, the reason why advertisers spend so much advertising to fit to 18 to 35 year olds is not because these customers spend more than that 35 to 55 year olds, but because they inherently understand that brand loyalty and brand preferences are often nurtured from a younger age.
Speaker 1 [00:18:18] So on that the lifetime value of a customer, right, an LBC model, we always want to think about that. Any brand you drive a Mercedes, an Audi, BMW, luxury car, just an example. They want to keep you in that vehicle as long as possible. With that, the form factors are going to change. And Scott, the lessons you learned or insights you learned at verb, do you forecast a rapid adoption of changing form factors down to these smaller robots that may be procedurally specific and the clinician’s ability to adopt those is standard of care?
Speaker 3 [00:18:51] No, no. You know, I, I think probably the thing I’m most frustrated in my 30 year career is that in medical devices, things don’t just take twice as long. They take three times as long as you’d like them to take. And that’s the reality that we have to face. We we may say we know it’s the right thing. It just takes a lot longer to get there, whether it’s regulatory, clinical, product, development, market adoption. So I can see the future in 20 years and what it’s going to be. It’ll have its ups and downs to get get to there with application specific connected, you know, robots with more specific tools and better form factors over time would be my my prediction. And I think that has to be taken into account relative to the venture investing that’s taken place where there was this mad rush and probably over funding of of robots when you consider, you know, really the clinical benefit, the cost and the accessibility didn’t really match the amount of capital it was putting put into the space. And now I think we’re we’re we’re getting into a more realistic view on, on timing of adoption and the real clinical benefits of these products.
Speaker 1 [00:20:05] Mike, when you think about developing a robot and it defending a position such as the end or tools that you have, some of that’s a defensive play, some is opportunistic. How how does Medtronic think about satiating the emerging market of roboticists? If you’re not a digital native per se, respectively.
Speaker 4 [00:20:32] That’s a that’s a big question, Joe.
Speaker 1 [00:20:34] That’s why they call me.
Speaker 3 [00:20:37] I gave it to you.
Speaker 4 [00:20:38] Yeah. That’s a that’s that’s a tough one. So I maybe I’ll answer it in this way that I think if I if I look at 10 or 20 years, I think there’ll be a significant consolidation of all these players into a few big ones that will offer multiple products and applications across a variety of fields. But they’ll still be those niches that are out there, including, I think what you’re implying maybe the the opportunities in in in countries that don’t have as much spend on health care or in rural hospitals here in the U.S. or maybe even in Amatory surgical centers where cost is is more critical that there still be an opportunity to meet a specific need. I don’t know if that might be, you know, sort of hybrid systems like a digital digital motion where, you know, they’re going to do some of the procedure laparoscopically. And I could do some of it robotically and maybe be able to remove a surgical assistant. But thinking of of, you know, unique solutions to fit those needs of those markets, I think for us, as Medtronic will try and capture as much as we can with a platform that we intend to to build on, but we’re not going to be able to meet everybody’s needs in all cases.
Speaker 1 [00:22:01] Greg, when you’re navigating where you’re heading now with distal motion, what what do you see as the largest barrier right now, technology or finances?
Speaker 5 [00:22:13] Yes. I may have gotten a harder question. At least I didn’t have to decipher what the words were. Yeah, I mean, I, I, I think both are barriers, but I would say, honestly, the reason that robotics isn’t, you know, through low acuity cases and as Scott said, you know, penetration is 10 to 15%. And outside the US it’s much, much lower in these, you know, general surgery gynecology some of these markets is is price. I mean, don’t be don’t be fooled. I mean it is it’s that anvil to a nail. As I said earlier, you can’t justify the cost for the benefit. So I mean I mean, you know, we talk about the definition of robotics, you know, and I would say we have the luxury at distal motion. You can do the surgery fully robotically. You can put the machine with a straight stick if you want, on a hernia. But the benefit is wristed instruments, right? So the suturing dissection and working in confined space on any robot is that’s a huge value to a surgeon. There is no question. And that, you know, I think that understanding in the marketplace and especially now when you talk about fellows and residents coming out, there are people that don’t even know how to do laparoscopic surgery. Right? To do a hernia, they need a robot. So I would say we have to we have to lower the barrier financially. I mean, again, if you look at, you know, the current market players, the cost is only going up. I mean, right. The next model is a 20% premium. So there’s got to be some segmentation as as you know, this talk is is called we have to have segmentation in this market because the adoption is going to come and it can’t come at the sake of, you know, profit for a business or, you know, to to really, in the long run hurt the patient. Right. Economically hurt the patient. So we’ve got to we’ve got to have a balance. And I think we’re getting there. One other comment. I do agree with Scott. One of the things that I learned, you know, over the past 6 or 7 years is utilization. And actually being able to use the tool on a broad basis is really, really important. So when you think about some of these niches of products and again, they may solve big, they have to solve huge clinical problems, in my opinion, to justify ROI. Even if it’s a 30 or $40,000 device. They have to solve a huge clinical problem, maybe rather than, you know, other other tools that go across that robotic spectrum.
Speaker 1 [00:24:39] Scott, you first. And Neville, in your opinion on this? The innovation on the robotics side always comes external from the large strategics, the larger teams, the greater distribution support, a sort of service sales, etc. is the build to buy model, one that is gaining traction in MedTech finally, as it is in biotech. And is that a pathway forward to address the stratification issue?
Speaker 3 [00:25:07] Yeah, that’s a non robotics question. Is that the intention? Yeah. Okay. Because. Because absolutely. I mean the verb surgical is a perfect example. Like you can all read about it publicly. Now, Joe sent me the nice, you know, Bloomberg law summary of the change, a verb or stuff. But you know, the idea that, you know, in four years you could ever build a robot that was on schedule to have a CE mark that wouldn’t have been possible to do within a JNJ environment. Now, within a changing environment, you’re back under all of those legal regulatory, quote, challenges that have just kept pushing, you know, timelines out. But I you know, I’m on the board of Vera Annex a big whole you know, part of our thesis is that, you know, the Medtronic’s the JNJ is all of them have incredible balance sheets, but they all have UPS objectives on their income statements and limitations. So they’d like to do more that they could put more into their interest. So, hey, how can I do organic growth, inorganic group growth or off balance sheet transactions of build a buy for a specific application? And so I’m involved in two other ones where large strategics and and VCs have put, you know, upwards $150 million. There’s an option for the strategic to buy it after four years when you get regulatory approval at 600 million. And, you know, it’s a perfect, you know, working model because you can have that kind of intrapreneur ship entrepreneurship focus of a startup team that’s done it before. I and then you’re delivering a product exactly what that strategic wants to fit into their channel. And that could be anything from a regulatory trial, a product extension or a whole new product category. So I see it as a huge opportunity for, you know, Medtronic’s, the strikers, the JJ, all the the Bostons, etc. to just go faster. It’s another lever lever to pull and leverage their balance sheet in order to do it.
Speaker 1 [00:27:11] And I bring it up in the robotics because I don’t think there’s a category that has a more massive requirement of finances in order to get a product over the line into clinical use, where if I’m using a PFA catheter, it’s not quite the lift. That’s right. No, the burden. Evelyn, thoughts on that subject?
Speaker 2 [00:27:26] Yeah, having done quite a few due diligence is for strategics and just having observe the market, I, you know, we think that strategic will continue to have their own robotics programs but still keep an eye and ear is really close to the ground for interesting technologies or companies that can augment or supplement their existing portfolio. I think another point here I wanted to raise was that, you know, high prices have been moving from the high acuity inpatient settings to the low acuity ASC settings for the last number of years. And in fact the ASC share procedures has doubled over the last five years. And in the really near future, it’s expected that the ASC will become the site of care for the majority of orthopedic procedures. So strategics are thinking about robotics, not just a way for them to gain revenues through the sale of the robot itself across the different acuity settings, but but from the associated implant and consumable as well. Like if you ask our surgeon if access to a particular robot impacts their choice of implant, the answer is probably going to be no. However, once the robots actually place in a certain setting the surgeons impressions and openness to the associated implant increases. And what we are seeing is that on average practices with a certain robot increase the usage share of that associate implant substantially. And so robotics and the implants, I really are really living in that same ecosystem. And so we think that strategics will continue investing in robotics for them to defend, to share in robotics, but also in the associated implant and consumable space.
Speaker 1 [00:29:03] Like we got to get that stapler going on, Hugo, if that’s the case.
Speaker 4 [00:29:08] I mean, I could talk a little about just innovation in general because. Totally agree that usually external innovation can go a lot faster than within the organization. Electronic And we have our ventures group and and other relationships that help accelerate some of those things. But there’s also a big challenge in integrating it into a robot. And I think Scott was alluding a little bit to this that, you know, from a regulatory standpoint, from A, B and B, I mean, robots unbelievably complicated. It’s not, as you were talking about, a PFOA ablation catheter or something. You got all the software, you’ve got all of the hardware, and it can be incredibly difficult. And I think for the group to kind of figure that out. And of course, we’re trying to push to do this, but figured out that systems engineering, that systems integration capability to accept third party innovation and build it onto a robot and be able to do that verification validation, get the regulatory approvals, you know, could really accelerate their offering in the marketplace. I think one of the things that that might be more along the lines of that kind of innovation is really on things like visualization and on the digital platforms, software related things that that can be in theory integrated a little bit faster. You know, software is still very complicated to test, but I think those are some of the opportunities that, you know, you can really accelerate and build off of a hardware platform.
Speaker 1 [00:30:34] Let’s go to the business model for a second here. Now let’s go to Aces in particular. We’ve got them owned by firms, surgeons and even let’s call it hospitals as well. And it’s a different selling model. I think Scott touched on it earlier. It’s a different supply chain model. Or Greg, you might have and. What are the robotic companies set up today or the business models set up today who sell to an institution? Now ready to sell to a decentralized provider network. And then what does that future look like? When I’m in Open Zipper, Iowa, Iowa with an ASC and I’ve got single use and I’ve got to supply that and keep those cases running. So, Greg, you’re going to have to solve that sooner than later.
Speaker 5 [00:31:24] Yeah. So I mean, we’re starting with single use for this very reason, but over the next year and a half we’ll have optionality and in reusable and again, all based on site of care. You know, I think my funny enough, the biggest learning I have is from orthopedics because it’s great to get a robot in the amount of instrumentation that comes along with that robot. And if you’re in the middle of Iowa and you have a premium brand new system, it’s it’s very difficult. I mean, I know every company is looking at, you know, offsite, sterile, I mean, offsite sterilization, how logistically you can move in and out, you know, instruments. And again, our methodology is simple. Keep it keep it very simple. We have five instruments. We’ve done a thousand surgeries in Europe, over 35 different types of procedures, low and high acuity. We don’t need much more. So again, when you have that philosophy, it doesn’t matter if the accounts in Tibet or Iowa, we can service them all, you know, then it just becomes economics. You know, if you can if you can delight them clinically. So I again, like logistics. You know, when I say logistics, I mean instrumentation, logistics and all the things that are needed to serve that robot. I mean, you have to consider what the sterilization capabilities are in those hospitals or, you know, I should say, alternative sites of care. And then you have to match them. They’re not going to put in a massive sterilizer to adopt a robot. Right. So, again, is everyone there yet? Absolutely not. There’s a lot of technologies that are just not there. And if you if you talk about any anybody that’s adopted robotics, the one of the biggest costs outside of the acquisition of the robot is the inventory. You know, so if you’re if you have five robots and you need 15, 20 sets of instruments times in, every set has four instruments times 15 uses, you can do the math on what that would cost to hold that type of inventory. So that’s impossible at an SC, they can’t do that. The business model doesn’t support it.
Speaker 1 [00:33:30] So what is the answer? Because that’s going to be critical to the adoption of these Scott.
Speaker 3 [00:33:35] Consignment and raise more capital. But his trust to raise $150 million. That’s right. I mean, right. I mean, you can figure out consignment and pricing models for volume discounts and that’s good.
Speaker 2 [00:33:49] Yeah. If I can just raise a point here. So we’re having work this some global logistics health care companies that they are very well aware of this this unmet need and also of course, this business opportunity for them. So they are thinking about developing a network of localized inventory and management centers. That service not just the ACS, but all the health care facilities in that localized area, and providing even just in time delivery for perhaps single use products. Even. The question is if they can do all this inventory management and delivery in a really accountable way, what is true blockchain technology or what it is, and also be able to deliver it in a cost efficient manner. So it’s definitely something that they are working on and possibly this inventory management responsibility could be solved by a new entrant.
Speaker 1 [00:34:39] But you have to address that when you’re coming out with you going intention is can they ask us?
Speaker 4 [00:34:44] Yeah, I mean, obviously we’re focused really on on, you know, significant acute care hospitals now but I think the is we think down the road I think there’s a certainly the logistics has been spoken to. But I think that there’s also a technical solution for things like training, simulation or other things that you typically see a sales rep or other clinical specialists that are present typically in hospitals today are going to have to be taken over, I think, by some of these other technical types of solutions. TelePresence, you know, these simulation things that you don’t have to have somebody physically on location in the middle of Iowa every single time to support. So I think there’s going to be an evolution in the development of some technical solutions as well.
Speaker 3 [00:35:31] Maybe adding to that one frustration that I’ve had. In this whole area relative to adoption and democratization is if you look at verb like, I wanted to create a Switzerland platform, Google said, Great, let’s create a Switzerland digital platform that can make all these devices, whether it’s, you know, Charlie’s over there for the whole store, it’s Imogene Strike or Imogene the Robot, you know, up to the cloud, surgical training, telepresence, whatever it might be. But everybody kind of wants their own version of that. So now then I went to digital surgery, which these guys bought. Then they said, okay, that didn’t work because they bought it. Now we still don’t have a Switzerland platform. Now that our proxy and the challenge is the hospital doesn’t want to buy it because they don’t want the added cost. The the vendor does want to buy because I don’t want but you need it to drive this vision that we’re all all talking about. That’s one of the things that we got to figure out. Now, I like your model because you’re open platform and you’re you’re working with proximity. So I like that.
Speaker 5 [00:36:31] I was I was going to say that if you did.
Speaker 3 [00:36:34] Go ahead. But how did you get to the decision to work with them were and now we’re in further discussions with multiple strategics, you know, as a Switzerland platform to drive a lot of those training, telepresence, our efficiencies, etc., apps on a platform with an open platform.
Speaker 5 [00:36:50] But yeah, so I’m going to say a couple of things. Number one, I’ll go back to the master of everything. You can’t master everything. So part of our strategy is partnership, of which we we inked a deal with Proxima in December. But what it does for us, you know, you just said it. It allows us to be in every area so we can now, you know, now we can not only from a sales and marketing perspective can we have people see what we’re doing, but we can also teach and train. We can have virtual proctoring. But that really is, in my opinion, not the source. The source is now we have a data infrastructure, we have cloud based services, and we can go from high touch, which robotics. Right now most companies are very high touch meaning rep in the room almost on every case. And with technologies or platforms like proximity, the idea is you can have a cockpit to do it. So, you know, we just motion I mean, it’s not a sustainable business model to put a rep in every case. That doesn’t make any sense at all for us. So we’re really focused on this high touch to low touch model where now we can get the benefit of technology and still delight the customer and serve the customer in the way that they expect.
Speaker 1 [00:38:01] Going down the panel level And starting with you, what what are the unlocks over the next five years in this stratification and what are the major barriers that are going to have you worried? Glad you got it. Yeah. Yeah. We’re all going to get it. You got it first. Yeah. While she thinks about. Is there anybody else who wants to jump?
Speaker 3 [00:38:23] Yeah. Look, I think it’s. There are no silver bullets. There’s. There’s a lot of individual things that. And when you add them together, make a difference. So I’ll be self-promoting with another company. I’m involved as that on the board. On target. So. Okay, we want to move to minimally invasive lung surgery. They talked about lung surgery this morning. Intuitive. Now, I moved to that in a robot. Well, now I can’t palpate. So now what I do now I’ve got, you know, a huge unmet need. I can identify through visualization where these lesions are actually out and I can have boundaries, and now I can make that a reality. So as we tackle each of these, they’re going to have their own challenges to make that surgery faster, better or cheaper. And the robotics are going to be a part of it, a digital platform. And learning and training is going to be a part of it. Imaging agents, I think, are going to be a huge multibillion dollar part of that as well. But we got to solve some of this economics. And I believe that a big part of that is JNJ getting in the market with the robot, Medtronic getting to a robot, having bundle deals where you saw what happened like Cordis selling 4 or $5000 drug eluting stents. Now, what’s a drug eluting stent cost four when there’s eight competitors and everything else, they’re under $1,000. Edwards first perk containing spouse. Now we have 3 or 4. But Intuitive has not had to have any competition. So go, Medtronic, go change, get your robots out. And I think it’ll be better for patients because it’s going to become more accessible.
Speaker 1 [00:39:53] Mike, you want to add to that?
Speaker 4 [00:39:55] Yeah, I think, you know, I agree with a lot of what what Scott is saying. I think that the the idea over the next five years is really finding those things that are being identified and being able to incorporate them into a platform. I don’t work for intuitive, but what I took away from the Gen five innovation or launch was actually sticking to the same platform that made it easier to use. They I think there’ll probably be there’s probably a bunch of stuff that’s embedded in there that can be turned on and off. That might be one way to offer to different markets. You turn on and off features allow people to select what things and how much they want to spend for some of that capability, but they can incorporate or we can incorporate some of that same capability, whether it’s an on target multispectral and our visualization system, some other kinds of tools that might be helpful proximity platform, other other other solutions like that that can be integrated to make it fit as many needs as we can. But but the barrier I guess the second part of your question again, I think is the regulatory part. And again, again, I don’t work for intuitive, but I think the fact that they use pretty much the same platform tweaked it helped accelerate their regulatory approval rate and they got approval for all all indications right away. And so I think that I don’t think you’re going to see big platform changes over time. I think you’ll see incorporating around the edges.
Speaker 3 [00:41:26] Everyone.
Speaker 2 [00:41:27] Yeah. So I agree with my fellow panelists. I think one thing that companies need to think about is not just like the clinical value of the product itself, but also how the surgeon thinks about themselves and how a surgeon defines a successful surgeon. Because your top three priorities are pretty much always the same. Like they want to grow their business. They want to have an incredible reputation in the in in the community that they’re working with. And they want to have great patient outcomes, whether or not it’s real breadth through robotics or whether it’s just two conventional methods. And so when companies think about approaching that, they need to think about how your robotic solutions actually match up against their top three priorities. And dressing these gaps would help to accelerate the growth.
Speaker 1 [00:42:12] Greg, you get the last word.
Speaker 5 [00:42:14] Yeah, So I’m not going to repeat. They’re all great points. I think the one that wasn’t mentioned is this data privacy cybersecurity element. So as soon as you connect with a device, there’s a whole different element of approvals and the ability to integrate within a hospital. So to me, that is going to be a big at first, probably a big limiter to speed because the smarter devices, the more conclusions that it will draw for you. I mean, there’s lines in the sand that you you know, when it starts to really assist with that outcome. And again, if you look at some of the the advanced visualization, I see it’s it’s consultative right now. It’s not it’s you know, so again, the more we get into this digital surgery is, as Scott mentioned earlier, I think the more difficult it’s going to become. And I think we’re going to have to work with the regulatory bodies to to get them there. I mean, you know, for all of us, I mean, I’m looking, you know, looking Medtronic and just a motion we have to go out and get, you know, multiple indications done to have, you know, these big vertical approvals. So it’s it’s a big it is a barrier for any company entering certain markets to try and get done so multifactorial there. But I you know I think there’s some work to be done to to really clear the path to true innovation.
Speaker 1 [00:43:33] Awesome. Well, I want to thank my panel. But a big for the panel. Thanks.